Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pre-miR-125a-5p mimic
- Development stage
- Preclinical
- Lead developer
- CINVESTAV
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
pre-miR-125a-5p mimic is a synthetic, double-stranded RNA molecule designed to replicate the biological activity of the endogenous tumor suppressor microRNA, miR-125a-5p. In various malignancies, including cervical carcinoma, miR-125a-5p expression is frequently downregulated, which facilitates tumor progression. By introducing this mimic, researchers can restore miR-125a-5p levels, which subsequently binds to the 3' untranslated regions (UTRs) of specific target mRNAs such as MARK1 (Microtubule Affinity Regulating Kinase 1) and VEGF (Vascular Endothelial Growth Factor). This binding leads to mRNA degradation or translational repression, effectively downregulating these proteins and resulting in cell-cycle arrest, inhibition of proliferation, and the induction of apoptosis. It is primarily utilized as a research tool to investigate miRNA-mediated gene regulation and potential therapeutic strategies in oncology.
- Brand names
- Pre-miR
- Other names
- miR-125a-5p mimicmiR125a-5p mimicmiR 125a-5p mimichsa-miR-125a-5p mimichsa-miR125a-5p mimichsa-miR 125a-5p mimic
02
Targets
BCL-2 (BCL-2 family)Vascular endothelial growth factor A messenger RNA 3′ untranslated regionMARK1 (Microtubule affinity regulating kinase 1)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on pre-miR-125a-5p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pre-miR-125a-5p mimic.